Jounce opts to join Concentra and reject Redx

27 March 2023

Cancer immunotherapies and predictive biomarkers company Jounce Therapeutics (Nasdaq: JNCE) has agreed to be acquired by Concentra Biosciences for $1.85 in cash per share plus a non-tradeable contingent value right (CVR).

This decision will come as a setback for UK-based Redx Pharma (AIM: REDX), which Jounce had recommended a business combination with in February via a proposed all share merger transaction, valued at around $425 million.

Less than a month later, Concentra Biosciences came in with an unsolicited offer to acquire 100% of Jounce, which had been struggling to finance further development of its immunotherapy candidates alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK